Active Ingredient History
Tedizolid phosphate is an oxazolidinone prodrug which in the body is dephosphorylated to the active compound tedizolid. The antibacterial activity of tedizolid is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis. Tedizolid inhibits bacterial protein synthesis through a mechanism of action different from that of other non-oxazolidinone class antibacterial drugs; therefore, cross-resistance between tedizolid and other classes of antibacterial drugs is unlikely. Tedizolid is bacteriostatic against Gram Positive bacteria such as enterococci, staphylococci, and streptococci. No drug-drug interactions were identified with tedizolid. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Skin Diseases, Bacterial (approved 2014)
Skin Diseases, Infectious (approved 2014)
Staphylococcal Skin Infections (approved 2014)
Abscess (Phase 2)
Bacterial Infections (Phase 3)
Bone Diseases, Infectious (Phase 2)
Cellulitis (Phase 2)
Cystic Fibrosis (Phase 4)
Diabetes Mellitus (Phase 1)
Erysipelas (Phase 2)
Gram-Positive Bacteria (Phase 1)
Gram-Positive Bacterial Infections (Phase 1)
Healthy Volunteers (Phase 1)
Kidney Failure, Chronic (Phase 1)
Liver Diseases (Phase 1)
Obesity (Phase 4)
Pneumonia (Phase 3)
Prosthesis-Related Infections (Phase 4)
Skin Diseases, Bacterial (Phase 3)
Skin Diseases, Infectious (Phase 3)
Wound Infection (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue